Alnylam Shows Efficacy, Safety With Lumasiran In Vulnerable Pediatric Patients
ILLUMINATE-B Is The Second Successful Phase III Study In Primary Hyperoxaluria 1
The top-line data in the ultra-rare disease are also the first to demonstrate safety and efficacy of an RNAi therapy in patients six years and younger.
